BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Evangelatos G, Koulouri V, Iliopoulos A, Fragoulis GE. Tuberculosis and targeted synthetic or biologic DMARDs, beyond tumor necrosis factor inhibitors. Ther Adv Musculoskelet Dis 2020;12:1759720X20930116. [PMID: 32612710 DOI: 10.1177/1759720X20930116] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Rath E, Bonelli M, Duftner C, Gruber J, Mandl P, Moazedi-furst F, Pieringer H, Puchner R, Flick H, Salzer HJF, Weiss G, Winkler S, Skvara H, Moschen A, Hofer H, Feurstein J, Sautner J. Consensus Statement der Österreichischen Gesellschaften für Rheumatologie und Rehabilitation, Pneumologie, Infektiologie, Dermatologie und Gastroenterologie zum Umgang mit latenter Tuberkulose bei Therapien mit biologischen oder „targeted synthetic“ DMARDs („disease modifying antirheumatic drugs“). Z Rheumatol 2022. [DOI: 10.1007/s00393-022-01274-6] [Reference Citation Analysis]
2 Fragoulis GE, Nikiphorou E, Dey M, Zhao SS, Courvoisier DS, Arnaud L, Atzeni F, Behrens GM, Bijlsma JW, Böhm P, Constantinou CA, Garcia-diaz S, Kapetanovic MC, Lauper K, Luís M, Morel J, Nagy G, Poleverino E, van Rompay J, Sebastiani M, Strangfeld A, de Thurah A, Galloway J, Hyrich KL. 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2022. [DOI: 10.1136/ard-2022-223335] [Reference Citation Analysis]
3 Koo T, Baek G, Jue MS. Risk of tuberculosis infection and serial changes in interferon-gamma release assays in elderly patients with psoriasis receiving biologic therapy. J Dermatol 2022. [PMID: 35619545 DOI: 10.1111/1346-8138.16471] [Reference Citation Analysis]
4 Ramírez-Marín HA, Tosti A. Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata. Drug Des Devel Ther 2022;16:363-74. [PMID: 35210753 DOI: 10.2147/DDDT.S334727] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Park DW, Kim YJ, Sung YK, Chung SJ, Yeo Y, Park TS, Lee H, Moon JY, Kim SH, Kim TH, Yoon HJ, Sohn JW. TNF inhibitors increase the risk of nontuberculous mycobacteria in patients with seropositive rheumatoid arthritis in a mycobacterium tuberculosis endemic area. Sci Rep 2022;12:4003. [PMID: 35256729 DOI: 10.1038/s41598-022-07968-w] [Reference Citation Analysis]
6 Tan S, Thong BY. Anti-tuberculous drug allergy: Diagnostic challenges. Clin Exp Allergy 2022;52:370-1. [PMID: 35194857 DOI: 10.1111/cea.14104] [Reference Citation Analysis]
7 Choe H, Kobayashi N, Ito Y, Ike H, Tezuka T, Takeyama M, Kawabata Y, Inaba Y, Singh VK. Detection of mecA and 16S rRNA Genes Using Real-Time PCR Can Be Useful in Diagnosing Iliopsoas Abscess, Especially in Culture-Negative Cases: RT-PCR for Iliopsoas Abscess. BioMed Research International 2022;2022:1-7. [DOI: 10.1155/2022/2209609] [Reference Citation Analysis]
8 Martins LVDO, Sacilotto NDC. Interleucina-6. Rev Paul Reumatol 2021. [DOI: 10.46833/reumatologiasp.2021.20.3.12-21] [Reference Citation Analysis]
9 Fragoulis GE, Brock J, Basu N, McInnes IB, Siebert S. The role for JAK inhibitors in the treatment of immune-mediated rheumatic and related conditions. J Allergy Clin Immunol 2021;148:941-52. [PMID: 34450118 DOI: 10.1016/j.jaci.2021.08.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
10 Avsar K. Tuberkulose - Wann daran denken, wie diagnostizieren? CME 2021;18:9-19. [DOI: 10.1007/s11298-021-2038-7] [Reference Citation Analysis]
11 Yang K, Oak ASW, Elewski BE. Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review. Am J Clin Dermatol 2021;22:173-92. [PMID: 33301128 DOI: 10.1007/s40257-020-00578-0] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 30.0] [Reference Citation Analysis]
12 Giannotta JA, Fattizzo B, Cavallaro F, Barcellini W. Infectious Complications in Autoimmune Hemolytic Anemia. J Clin Med 2021;10:E164. [PMID: 33466516 DOI: 10.3390/jcm10010164] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]